The functional role exhibited by RUNX3 is very similar to the role CD82 plays in prostate cells, i.e., CD82 reexpression has been shown to inhibit EMT (36), inhibit migration and invasion (30) and its down-regulation has been correlated with poor prognosis (2–4) in prostate cancer. Here, RUNX3 is linked to prostate cancer.